GARDP welcomes additional funding from UK to develop new treatment for gonorrhoea

This investment, on top of £3.5 million committed in 2019, will support the Global Antibiotic Research and Development Partnership (GARDP) in the development and availability of zoliflodacin, a novel antibiotic, which is currently being assessed as part of a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.

This new antibiotic has the potential to treat drug resistant gonorrhoea and is one of the few antibiotics in development specifically for the disease, an important consideration to ensure the treatment remains effective for generations to come.